HOLLISTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society of Toxicology (SOT) conference from March 11-13, 2024, in Salt Lake City. Complementing an already extensive product line, the new innovations provide exciting new opportunities for advancing preclinical and organoid-focused therapy development.

DSI™ Ponemah™ Data Management Platform Provides Integrated Preclinical Solution

The Company’s industry-leading GLP-compliant Ponemah™ preclinical data management platform now includes integrations with the new SoHo™ implantable telemetry solution and the VivaMARS™ high-capacity behavior monitoring system.

By integrating these new applications in a single data management platform, the Ponemah system provides users with a powerful tool for managing and analyzing data across a range of studies. The integrated platform also opens new opportunities for the use of emerging machine learning-based algorithms to efficiently analyze large data pools.

SoHo™ Implantable Real-Time Telemetry for Small Animal Models

Together with the Ponemah platform, the SoHo telemetry solution enables researchers to collect, manage, analyze and report findings from multiple concurrent small animal models in a more natural shared housing environment. In addition, the SoHo solution allows data to be collected over longer time periods and opens exciting new opportunities for longitudinal studies. SoHo supports the customer’s business needs by reducing operating costs and test cycle times, enabling increased testing throughput. For more information visit the DSI website at https://www.datasci.com/products/implantable-telemetry/soho-telemetry-system.

VivaMARS™ Activity Monitoring System

The VivaMARS system combines the Company’s infrared Panlab^® activity monitoring technology with its Ponemah platform to create an integrated, GLP-compliant solution for real-time, high precision behavioral testing. The system is ideally suited to meet the high throughput, automated neuropharmacology and neurotoxicology testing needs of CROs and pharma companies, in addition to longitudinal behavior studies carried out by leading research and academic institutes. For more information on the VivaMARS system, visit the DSI website at https://www.datasci.com/products/behavior/vivamars-mobile-activity-rack-system.

MCS™ Mesh MEA™ Organoid Platform

The Company will also exhibit its new organoid-centric mesh Microelectrode Array (MEA) platform. Expanding on its recognized leadership position in in-vitro MEA products, the new Mesh MEA™ platform allows researchers to capture precise electrophysiology measurements from inside the living organoid in real time. The new Mesh MEA platform is designed for the emerging applications of organoids in research and discovery, safety pharmacology and toxicology. For more information on our mesh MEA products and organoid research, visit our website at https://www.harvardbioscience.com/applications/organoid-research.

Solutions for New Therapy Development

Jim Green, Harvard Bioscience Chairman and CEO, said, “We are pleased to offer our CRO, pharma, and biotech customers innovative products designed to reduce cycle times, improve throughput, and reduce time to market. Looking to the future, I’m especially excited by the potential of our Ponemah platform to advance the use of emerging artificial intelligence (AI) and machine learning technologies to streamline data analysis and reporting in applications such as toxicology and organoid testing.”

Serge Savard, Harvard Bioscience Vice President of Product Management, said, “By integrating these new applications in a single data management platform, our Ponemah system provides a proven solution for preclinical testing. And, with the emergence of new machine learning technologies and their potential to automate the analysis and review of large data sets, we are already starting to receive customer interest in extending the Ponemah platform to incorporate these technologies.”

Booth at Society of Toxicology

The Company will be exhibiting a range of solutions at Society of Toxicology booth #2304, at the Salt Palace Convention Center (Salt Lake City, UT). Representatives will be present during exhibit hours from Monday, March 11, 2024 through Wednesday, March 13, 2024.

About Harvard Bioscience

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at https://www.harvardbioscience.com.

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational performance including revenues, gross margins, earnings, cash and debt position, growth and the introduction of new products, and the strength of the Harvard Bioscience, Inc. (the “Company”) market position and business model. Forward-looking statements are not guarantees of future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s actual results to differ materially from those described its forward-looking statements include those described in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K as well as in the Company’s other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.

Inquiries:

Customers
Sales@datasci.com

Investors and Media
Harvard Bioscience, Inc.
Investor Relations
investors@harvardbioscience.com
(508) 893-3120